医学
秋水仙碱
心肌梗塞
痛风
冲程(发动机)
内科学
心脏病学
疾病
药品
动脉粥样硬化性心血管疾病
药理学
机械工程
工程类
标识
DOI:10.58347/tml.2023.1686b
摘要
Colchicine (Colcrys, and others), which has been available in the US for decades for prophylaxis and treatment of gout flares and other indications in oral formulations that contain 0.6 mg of the drug, has now been approved in 0.5-mg tablets as Lodoco (Agepha) to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple risk factors for cardiovascular disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI